Cognitive Impairment - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/09/2013 -- Reportstack, provider of premium market research reports announces the addition of Cognitive Impairment - Pipeline Review, H2 2013 market report to its offering
Cognitive Impairment - Pipeline Review, H2 2013


, 'Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Cognitive Impairment - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Cognitive Impairment.
- A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Eli Lilly and Company
Athersys, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Avineuro Pharmaceuticals, Inc.
Novartis AG
Chiesi Farmaceutici SpA
Laboratoires Pierre Fabre SA
Pfizer Inc.
Evotec Aktiengesellschaft
Lupin Limited
Bionomics Limited
Paladin Labs Inc.
Theratechnologies Inc.
Suven Life Sciences Ltd.
Mithridion, Inc.
Upsher-Smith Laboratories, Inc.
Celon Pharma Sp. z o.o.
AGY Therapeutics, Inc.
PsychoGenics, Inc.
QR Pharma, Inc.
Siena Biotech S.p.A.
SeneXta Therapeutics SA
Dart NeuroScience LLC
Omeros Corporation
Adeona Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc.
Targacept, Inc.
Galenea Corp.
M's Science Corporation
Heptares Therapeutics Ltd.
Pacific Northwest Biotechnology, LLC
Pherin Pharmaceuticals, Inc.
PhysioGenix, Inc.

To view the table of contents for this market research report please visit